M
Maria E. Cabanillas
Researcher at University of Texas MD Anderson Cancer Center
Publications - 205
Citations - 8700
Maria E. Cabanillas is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Thyroid cancer & Cancer. The author has an hindex of 42, co-authored 169 publications receiving 5790 citations. Previous affiliations of Maria E. Cabanillas include Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah,Robert J. Kreitman,Zev A. Wainberg,Jae Yong Cho,Jan H.M. Schellens,Jan H.M. Schellens,Jean-Charles Soria,Patrick Y. Wen,Christoph C. Zielinski,Maria E. Cabanillas,Gladys Urbanowitz,Bijoyesh Mookerjee,Dazhe Wang,Fatima Rangwala,Bhumsuk Keam +14 more
TL;DR: Dabrafenib plus trametinib is the first regimen demonstrated to have robust clinical activity in BRAF V600E-mutated anaplastic thyroid cancer and was well tolerated, representing a meaningful therapeutic advance for this orphan disease.
Journal ArticleDOI
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
Lori J. Wirth,Eric J. Sherman,Bruce G. Robinson,Benjamin Solomon,Hyunseok Kang,Jochen H. Lorch,Francis P. Worden,Marcia S. Brose,Jyoti D. Patel,Sophie Leboulleux,Yann Godbert,Fabrice Barlesi,John C. Morris,Taofeek K. Owonikoko,Daniel Shao-Weng Tan,Oliver Gautschi,Jared Weiss,Christelle De La Fouchardiere,Mark E. Burkard,Janessa Laskin,Matthew H. Taylor,Matthias Kroiss,Jacques Medioni,Jonathan W. Goldman,Todd M. Bauer,Benjamin Levy,Viola W. Zhu,Nehal Lakhani,Victor Moreno,Kevin Ebata,Michele Nguyen,Dana Heirich,Edward Y. Zhu,Xin Huang,L. Yang,Jennifer Kherani,S. Michael Rothenberg,Alexander Drilon,Vivek Subbiah,Manisha H. Shah,Maria E. Cabanillas +40 more
TL;DR: In this phase 1-2 trial, selpercatinib showed durable efficacy with mainly low-grade toxic effects in patients with medullary thyroid cancer with and without previous vandetanib or cabozantinib treatment.
Journal ArticleDOI
Selective RET kinase inhibition for patients with RET-altered cancers
Vivek Subbiah,Vamsidhar Velcheti,Brian B. Tuch,Kevin Ebata,Naifa L. Busaidy,Maria E. Cabanillas,Lori J. Wirth,S. Stock,Steven J. Smith,V. Lauriault,S. Corsi-Travali,Dahlia Henry,Mark E. Burkard,R. Hamor,Karyn Bouhana,Shannon L. Winski,R. D. Wallace,D. Hartley,S. Rhodes,M.G. Muni Reddy,Barbara J. Brandhuber,Steve Andrews,Stephen M. Rothenberg,A. Drilon +23 more
TL;DR: These results provide proof-of-concept of the clinical actionability of RET alterations, and identify selective RET inhibition by LOXO-292 as a promising treatment in heavily pretreated, multikinase inhibitor-experienced patients with diverse RET-altered tumors.
Journal ArticleDOI
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
Marcia S. Brose,Maria E. Cabanillas,Ezra E.W. Cohen,Lori J. Wirth,Todd Riehl,Huibin Yue,Steven I. Sherman,Eric J. Sherman +7 more
TL;DR: Vemurafenib showed antitumour activity in patients with progressive, BRAF(V600E)-positive papillary thyroid cancer refractory to radioactive iodine who had never been treated with a multikinase inhibitor.
Journal ArticleDOI
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells
Chad Tang,James W. Welsh,Patricia M. de Groot,Erminia Massarelli,Joe Y. Chang,Kenneth R. Hess,Sreyashi Basu,Michael A. Curran,Maria E. Cabanillas,Vivek Subbiah,Siqing Fu,Apostolia Maria Tsimberidou,Daniel D. Karp,Daniel R. Gomez,Adi Diab,Ritsuko Komaki,John V. Heymach,Padmanee Sharma,Aung Naing,David S. Hong +19 more
TL;DR: Combining SABR and ipilimumab was safe with signs of efficacy, peripheral T-cell markers may predict clinical benefit, and systemic immune activation was greater after liver irradiation.